NEGXF (NexgenRx) FFO


NEGXF NexgenRx Inc NEGXF
51 GF Score
Price $0.33
GF Value $0.27
Valuation Modestly Overvalued
! 6 Warning Signs
View Full Analysis

What is NexgenRx FFO?

FFO (Funds from operations) only applies to REITs.

NEGXF
51GF Score
NexgenRx Inc NEGXF
FFO is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is NexgenRx (NEGXF) Overvalued in 2026?

Based on GuruFocus' analysis, NexgenRx stock appears to be overvalued. The current stock price of $0.33 is trading 20.4% above its estimated GF Value™ of $0.27. GuruFocus considers NexgenRx to be Modestly Overvalued.

Key valuation signals for NEGXF:

  • FFO:
  • GF Value™: $0.27 vs. price of $0.33 (20.4% above fair value)
  • GF Score™: 51/100 with 6 warning signs

No single metric tells the full story. See the NEGXF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

NexgenRx Business Description

Other Exchanges NXG:Canada
Address 191 The West Mall, Suite 905, Toronto, ON, CAN, M9C 5L6
NexgenRx Inc administers, adjudicates, and pays drug, dental and other extended health-care claims for the beneficiaries of health benefit plans underwritten by its customers using proprietary computer software and also provides ancillary services. The various solutions offered by the company include: NexSys, a fully integrated rules-based adjudication platform for real-time processing of drug, dental, and extended health benefit claims; NexAdmin, which enables sponsors to take complete control of benefit plan administration; and NexPSPAssist, a service that helps Patient Support Programs (PSP) to optimize their deliverables to their manufacturer clients. The company has only one operating segment - benefits administration services.
51GF Score

Get the complete analysis for NEGXF

FFO is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.33
Price
$0.27
GF Value